JNJ-64619178

DRUG3 trials

Sponsors

Janssen-Cilag International NV, Janssen Research & Development, LLC

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMetastatic Castration-resistant Prostate Cancer (mCRPC)Myelodysplastic SyndromesNeoplasmsNon-Hodgkin LymphomaNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer

Phase 1

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

CompletedNCT03573310

Janssen Research & Development, LLCMyelodysplastic Syndromes, Neoplasms, Non-Hodgkin Lymphoma +1

Start: 2018-07-13End: 2025-09-25Updated: 2025-12-18

A rollover study for continued study treatment and ongoing safety monitoring

RecruitingISRCTN87946208

Janssen-Cilag International NVNon-Hodgkin lymphoma and chronic lymphocytic leukemia Cancer

Start: 2024-12-31Target: 77Updated: 2025-03-31

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitationNCT06788509

Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4

Start: 2024-12-30End: 2028-01-21Target: 80Updated: 2025-10-10

Related Papers

Inhibition of PRMT5 with JNJ-64619178 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptosis

Blood2025-11-03

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

Blood2024-11-051 citations

Abstract C089: PRMT5 as a novel druggable vulnerability for EWSR1-ATF1-driven clear cell sarcoma

Molecular Cancer Therapeutics2023-12-01

Inhibition of PRMT5 Increases Sensitivity to BH3 Mimetics in Aggressive B Cell Malignancies

Blood2022-11-151 citations